Immunopharmacology and inflammationSuppressive effects of type I angiotensin receptor antagonists, candesartan and Irbesartan (cas 138402-11-6) on allergic asthma

Add time:08/26/2019    Source:sciencedirect.com

The effects of candesartan and Irbesartan (cas 138402-11-6), antagonists of the type I angiotensin II receptor, were investigated on allergic asthma. The antigen-induced degranulation was measured by evaluating β-hexosaminidase activity in vitro. Additionally, a murine ovalbumin-induced allergic asthma model was used to test the in vivo efficacy. It was observed that while candesartan inhibited the antigen-induced degranulation in rat RBL-2H3 mast cells, irbesartan did not. Administration of candesartan and irbesartan decreased the number of immune cells in the bronchoalveolar lavage fluid and reduced the expression of Th2 (IL-4, IL-5, and IL-13) and Th1 cytokines (IL-2 and IFN-γ) in the lung tissues of mice with ovalbumin-induced allergic asthma. Histological studies revealed that both antagonists reduced inflammation and mucin production in the lungs. Therefore, these findings provide evidence that candesartan and irbesartan could have potential applications as anti-allergic agents.

We also recommend Trading Suppliers and Manufacturers of Irbesartan (cas 138402-11-6). Pls Click Website Link as below: cas 138402-11-6 suppliers

Prev:Irbesartan (cas 138402-11-6) desmotropes: Solid-state characterization, thermodynamic study and dissolution properties
Next:The thermal decomposition mechanism of Irbesartan (cas 138402-11-6))